Trimetazidine

Trimetazidine is a drug for angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism, also known as fatty acid oxidation inhibitor.

·         Cas No: 13171-25-0

·         Chemical Composition: C14H22N2O3.2HCl

·         Molecular wt.: 339.26

·         Description: A white Crystalline Powder, Slightly hygroscopic.

·         Solubility: Soluble in water, sparingly soluble in ethanol & practically insoluble in ether

·         Heavy Metals: Limit: Max. 20 PPM

·         Arsenic: Limit :Max.2PPM

·         Ph of Solution ( 1 in 20): Limit : 2.3 to 3.3

·         Clarity And Colour of the Solution: Clear and Colourless Solution

·         Melting Point: Limit : 225o to 227o

·         Residue on Ignition: Limit : Max. 0.2 %

·         Loss on drying: Limit : Max.:2%

·         Assay: Limit: Min. 98%

 Packaging details: